Mr Crocker has over 20 years’ experience in pharmaceutical regulatory affairs and drug development, with significant expertise in the area of generic respiratory and inhaled medicines.
Since 1999, he has been Managing Director of PhRAction (formerly Pharmaxis), a pharmaceutical regulatory affairs and drug development consultancy, at which he was responsible for ten submissions of orally inhaled drug products to international regulatory agencies.
Before that, he held senior drug development regulatory affairs positions at Boehringer Ingelheim, Ethical Generics (now Genus Pharmaceuticals), Trinity Pharmaceuticals (now Trinity Chiesi), Norton Healthcare (now Teva EU) and Glaxo Group Research (now GSK).
Mr Crocker is a member of The Organization for Professionals in Regulatory Affairs (TOPRA).
Commenting on the appointment, David Hipkiss, Prosonix’ CEO, said: “Prosonix has taken several important steps to strengthen its product development capabilities since its £11.4 million fundraising in June 2011. We recently announced the formation of a new Scientific Advisory Board and we are also building our expertise in regulatory affairs and clinical development. Rob’s appointment is the next step and we expect his regulatory expertise, particularly submissions for generic respiratory medicines, to be crucial given our plans to file PSX1001, our lead drug candidate, for asthma in late 2012. We also expect him to play an important role in the planning and execution of our regulatory and clinical development strategies for PSX1002 and the PSX2000 series of combination medicines.”
Rob Crocker, said: “Prosonix’s novel approach to respiratory drug development and its unique particle engineering capabilities offer the potential to revolutionize respiratory drug development and deliver better products with significant benefits to patients. The Company is entering an exciting period of development and I am pleased to have the opportunity to contribute my regulatory expertise and experience to help it achieve its objectives of getting these new products to market.”